Hemispherx Biopharma Inc. has formed an agreement with Impatients N.V., a Netherlands-based company doing business as myTomorrows, for the commencement and management of an early access program (EAP) in all of Europe and Turkey.

myTomorrows, as Hemispherx’ exclusive service provider in Europe and Turkey, will perform EAP activities in Europe and Turkey to include the supply of rintatolimod for the treatment of chronic fatigue syndrome (CFS) to patients with an unmet medical need.

“We are very pleased to be collaborating with myTomorrows to provide rintatolimod under these unique EAPs,” said Thomas Equels, executive vice chairman and chief financial officer, Hemispherx. “Not only will this collaboration create the possibility for physicians to use rintatolimod under certain circumstances, myTomorrows will collaborate with these physicians to capture data on patients treated and such data may add to our other efforts to gain full regulatory approval in Europe, Latin America, Australia, New Zealand as well as the U.S. and elsewhere.”